Off-the-shelf CAR NK-cell therapy shows promise for relapsed or refractory AML

A study presented at the American Association for Cancer Research Annual Meeting 2025 found that the investigational chimeric antigen receptor (CAR) therapy SENTI-202 induced complete remission in patients with relapsed or refractory acute myeloid leukemia (AML).

Trispecific therapy ISB 2001 active in ongoing early myeloma trial

ISB 2001, a trispecific T-cell engager targeting BCMA and CD38, showed expected immune activity and no dose-limiting toxicities in an ongoing phase 1 study in relapsed or refractory multiple myeloma […]

RNA-seq maps genetic, nongenetic drivers of AML

Investigators used RNA sequencing to create a new gene activity atlas that showed how normal blood cells developed. The technique also identified the different ways abnormal development can lead to […]